Lung Cancer Europe Launches Groundbreaking Atlas to Address Unequal Access to Treatment Across Europe

Too many people living with lung cancer still face delays, limited access, or barriers to getting the diagnostics and treatments they need. Lung Cancer Europe (LuCE) has today launched the Access to Treatment Atlas – a major new advocacy tool designed to support efforts to improve equity across the continent.

The Access to Treatment Atlas is an interactive online resource created with and for patient advocates and other stakeholders. It brings together information from over 30 European countries on the availability of licensed lung cancer treatments and diagnostics – including biomarker testing – and highlights how access differs between countries.

Users can explore the data through an interactive map, with filters by country, treatment, biomarker, cancer type, stage of disease and line of treatment.

“This Atlas is a response to what advocates across Europe have been saying for years – that where you live still too often determines the care you get,” said Debra Montague, President of Lung Cancer Europe. “We hope this tool gives advocates and organisations the evidence they need to push for better access, faster decisions, and ultimately, fairer treatment for everyone affected by lung cancer.”

The Atlas has been developed by Lung Cancer Europe in collaboration with external partners, including the European Federation of Pharmaceutical Industries and Associations (EFPIA), European Respiratory Society (ERS), European Lung Foundation (ELF), European Society for Medical Oncology (ESMO), European Thoracic Oncology Platform (ETOP), and From Testing to Targeted Treatments (FT3).

While the Atlas is designed primarily for patient advocates, it will also be useful for researchers, clinicians, policy-makers, and anyone working to improve access to lung cancer care.

Important notice: The information on this website is not intended for use within the UK.

Explore the Atlas: https://atlaslungcancereurope.eu